

Alzheimer's disease clinical studies in the **Atlanta** area

Safety of Switching from Donepezil (Aricept®) to Rivastigmine (Exelon®) Patch in Patients with Probable Alzheimer's Disease

Sponsored by: Novartis
ClinicalTrials.gov #: NCT00428389
Study Phase: Phase III

Study Location(s) and Contact Information

Medical Associates of North Georgia
Cumming, Georgia, 30040, 770-889-7118

Medical Associates of North Georgia
Canton, Georgia, 30114, 770-479-5535

Study Purpose

This study is designed to evaluate the safety and tolerability of switching from donepezil (Aricept®) to a rivastigmine (Exelon®) patch in patients with probable Alzheimer's disease.

You May Qualify if You...*

- Are at least 50 years of age
- Have a diagnosis of probable Alzheimer's disease
- Have a caregiver who is able to attend all study visits
- Have received continuous treatment with donepezil (Aricept®) for at least 6 months prior to screening, and received a stable dose of 5 mg/day or 10 mg/day for at least the last 3 of these 6 months

You May Not Qualify if You...*

- Have a history within the past year or current diagnosis of cerebrovascular disease

- Have a history of malignant cancer within the past 5 years
- Have a current diagnosis of severe or unstable cardiovascular disease; have a history of heart attack in the last six months
- Have a severe or unstable respiratory condition, such as severe asthma or severe lung disease
- Have a disability that may prevent you from completing all study requirements

**These are not all the entry criteria, only the main criteria*

A Comparison of Two Standard Therapies in the Management of Dementia with Agitation

Sponsored by: Emory University
Abbott
ClinicalTrials.gov #: NCT00208819
Study Phase: Phase IV

Study Location(s) and Contact Information

Wesley Woods Geriatric Hospital
Atlanta, Georgia, 30329
R. D. Jewart, Ph.D., 404-728-6414
rjewart@emory.edu

Julie D. Rosenberg, 404-728-4784
jdrose4@emory.edu

Updated August 30, 2007

Continued...

This document is provided as a service of the Alzheimer's Association, using publicly available information. The Alzheimer's Association does not support or endorse any clinical study included in this document.

Alzheimer's disease clinical studies in the **Atlanta** area

Management of Dementia with Agitation Continued...

Study Purpose

The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex (Depakote®) is the most effective and safest way to treat agitation in elderly patients with dementia.

You May Qualify if You...*

- Are 65 Years or older
- Are admitted to Wesley Woods Inpatient service for dementia with psychosis and agitation
- Are taking risperidone (Risperdal®) (up to 1.5 mg/day), quetiapine (Seroquel®) (up to 175 mg/day), or olanzapine (Zyprexa®) (up to 7.5 mg/day)

You May Not Qualify if You...*

- Have had prior sensitivity to risperidone (Risperdal®), quetiapine (Seroquel®) olanzapine(Zyprexa®) or divalproex (Depakote®)

**These are not all the entry criteria, only the main criteria.*

MIRAGE: Multi-Institutional Research in Alzheimer's Genetic Epidemiology

Sponsored by: National Institute on Aging
ClinicalTrials.gov #: NCT00239759

Study Location(s) and Contact Information

Morehouse School of Medicine
Atlanta, Georgia, 30310

Jolita Wainwright, BS, 404-752-1877
jwainwright@msm.edu

Study Purpose

The goal of MIRAGE is to evaluate the association of genetic and non-genetic risk factors for Alzheimer's disease.

You May Qualify if You...*

- Have probable or definite Alzheimer's disease
- Have living siblings who do not have Alzheimer's disease
- Are 60 years old or older (with Alzheimer's disease) and your sibling(s) are 50 years old or over

You May Not Qualify if You...*

- Have a history of stroke
- Have a pacemaker

**These are not all the entry criteria, only the main criteria.*

Treatment of Subjects with Mild to Moderate Alzheimer's Disease and Sleep Disturbance with Rozerem®

Sponsored by: Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov #: NCT00325728
Study Phase: Phase II

Study Location(s) and Contact Information

Atlanta, Georgia
Teri Callaway, BS, 512-685-5781
teri.callaway@austin.ppdi.com

Updated August 30, 2007

Continued...

This document is provided as a service of the Alzheimer's Association, using publicly available information. The Alzheimer's Association does not support or endorse any clinical study included in this document.

For more information, call the Alzheimer's Association Clinical Study Hotline at **1-800-982-8299**

Alzheimer's disease clinical studies in the **Atlanta** area

Rozerem® Continued...

Study Purpose

The purpose of the study is to determine if subjects with mild to moderate Alzheimer's disease and sleep disturbance will benefit from Rozerem®.

You May Qualify if You...*

- Have been diagnosed with probable Alzheimer's disease
- Are 55 years old or older
- Reside in the same home with a primary caregiver
- Have a history of at least 2 sleep disorder behaviors, occurring at least once weekly over the two weeks before study entry

You May Not Qualify if You...*

- Cannot walk
- Do not have a caregiver with you during the night
- Have a history of stroke or vascular dementia

**These are not all the entry criteria, only the main criteria.*

Rosiglitazone (Extended Release Tablets) as Monotherapy in Subjects with Mild to Moderate Alzheimer's Disease

Sponsored by: GlaxoSmithKline
ClinicalTrials.gov #: NCT00428090
Study Phase: Phase III

Study Location(s) and Contact Information

GSK Clinical Trials Call Center
Decatur, Georgia, 30033
Michael Norman, 1-877-379-3718

Study Purpose

This study tests whether an extended-release form of Rosiglitazone (RSG XR) safely provides benefit to people with mild to moderate Alzheimer's disease. RSG XR is a new approach to Alzheimer's disease therapy and this study tests whether one's genetic makeup alters the effectiveness of RSG XR. RSG has been tested and is FDA approved as a treatment for type 2 diabetes.

You May Qualify if You...*

- Are between 50 and 90 years old
- Have a diagnosis of probable Alzheimer's disease
- Have not taken an approved Alzheimer's disease medication in the last 30 days
- Have no previous hypersensitivity/intolerance to medications called acetylcholinesterase inhibitors (such as Aricept®, Exelon® or Razadyne®)
- Have a regular caregiver

You May Not Qualify if You...*

- Have a diagnosis of vascular dementia
- Have type 1 or secondary diabetes mellitus
- Have type 2 diabetes mellitus treated with insulin or medications
- Have a history or evidence of congestive heart failure
- Have a history of significant psychiatric illness, major depressive disorder or current depression needing treatment

**These are not all the entry criteria, only the main criteria.*

Updated August 30, 2007

Continued...

This document is provided as a service of the Alzheimer's Association, using publicly available information. The Alzheimer's Association does not support or endorse any clinical study included in this document.

For more information, call the Alzheimer's Association Clinical Study Hotline at **1-800-982-8299**

Alzheimer's disease clinical studies in the **Atlanta** area

Rosiglitazone (Extended Release Tablets) as Additive Therapy for Subjects with Mild to Moderate Alzheimer's Disease

Sponsored by: GlaxoSmithKline
ClinicalTrials.gov #: NCT00348140
Study Phase: Phase III

Study Location(s) and Contact Information

GSK Clinical Trials Call Center
Decatur, Georgia, 30033
Marshall Nash, 1- 877-379-3718

Study Purpose

This study tests whether an extended-release form of Rosiglitazone (RSG XR) safely provides benefit to people with mild to moderate Alzheimer's disease when combined with one of the currently approved Alzheimer's disease medications such as Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to Alzheimer's disease therapy and this study tests whether one's genetic makeup affects their response to the RSG XR. RSG has been tested and is FDA approved as a treatment for type 2 diabetes.

You May Qualify if You...*

- Are between 50 and 90 years old
- Have probable Alzheimer's disease
- Have had at least six months of ongoing therapy with Aricept®, Razadyne® or Exelon®
- Have a regular caregiver

You May Not Qualify if You...*

- Have a diagnosis of vascular dementia
- Have type 1 or secondary diabetes mellitus

- Have type 2 diabetes mellitus treated with insulin or medications

**These are not all the entry criteria, only the main criteria.*

Short Term Effects of PRX-03140 in Patients with Mild Alzheimer's Disease Being Treated with Aricept®

Sponsored by: Epix Pharmaceuticals, Inc.
ClinicalTrials.gov #: NCT00384423
Study Phase: Phase II

Study Location(s) and Contact Information

Atlanta Center for Medical Research
Atlanta, Georgia, 30308
Kelly Calistri, 404-881-5800
kcalistri@acmr.org

Study Purpose

This is a study to evaluate PRX-03140 in subjects with mild Alzheimer's disease who are using a stable 10 mg dose of Aricept® (donepezil), but are experiencing a worsening of their Alzheimer's disease symptoms.

You May Qualify if You...*

- Have a diagnosis of probable mild Alzheimer's disease
- Are 60 years old or older
- Have been on a 10 mg dose of Aricept® for at least 90 days
- Are able to take your Aricept® in the morning

Updated August 30, 2007

Continued...

This document is provided as a service of the Alzheimer's Association, using publicly available information. The Alzheimer's Association does not support or endorse any clinical study included in this document.

For more information, call the Alzheimer's Association Clinical Study Hotline at **1-800-982-8299**

Alzheimer's disease clinical studies in the **Atlanta** area

PRX-03140 Continued...

You May Not Qualify if You...*

- Have dementia other than Alzheimer's disease
- Have Parkinson's disease
- Have a history of seizure or epilepsy
- Have enrolled in a previous study for PRX-03140
- Have used tobacco products within last 4 weeks

**These are not all the entry criteria, only the main criteria.*

DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease

Sponsored by: National Institute on Aging
Martek Biosciences Corporation

ClinicalTrials.gov #: NCT00440050

Study Phase: Phase III

Study Location(s) and Contact Information

Emory University Department of Psychiatry
Atlanta, Georgia, 30322
Rita Jewart, Ph.D., 404-728-6414
rjewart@emory.edu

Julie Rosenberg, BA, 404-728-4784
jdrose4@emory.edu

Study Purpose

The purpose of this study is to determine whether long-term DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease.

You May Qualify if You...*

- Are 50 years old or older
- Reside in the community at the start of the study (includes assisted living facilities, but excludes long-term care nursing facilities)
- Have supervision available for study medication
- Have a caregiver or study partner to accompany you to all visits; your partner must have direct contact with you more than 2 days per week
- Have been on a stable dose of Alzheimer's disease medication for at least 4 months

You May Not Qualify if You...*

- Have non-Alzheimer's disease dementia
- Reside in a long-term care facility
- Have had a significant stroke
- Have a history in the past two years of epilepsy, seizure or head injury with loss of consciousness
- Have any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse

**These are not all the entry criteria, only the main criteria.*

Updated August 30, 2007

This document is provided as a service of the Alzheimer's Association, using publicly available information. The Alzheimer's Association does not support or endorse any clinical study included in this document.